An update from Giant Biogene Holding Co. Ltd. ( (HK:2367) ) is now available.
Giant Biogene Holding Co., Ltd. has announced its upcoming annual general meeting scheduled for June 13, 2025, in Xi’an, Shaanxi Province, China. The meeting will address several key resolutions, including the re-election of independent non-executive directors, re-appointment of Ernst & Young as auditors, and granting general mandates for share repurchase and issuance. These resolutions are expected to impact the company’s governance and financial strategies, potentially influencing its market positioning and shareholder value.
More about Giant Biogene Holding Co. Ltd.
Giant Biogene Holding Co., Ltd. is a company incorporated in the Cayman Islands, operating within the biotechnology industry. The company is primarily focused on developing and providing biotechnological products and services, with a market emphasis on innovation and advanced scientific solutions.
YTD Price Performance: 54.51%
Average Trading Volume: 5,594,957
Technical Sentiment Signal: Sell
Current Market Cap: HK$78.84B
For a thorough assessment of 2367 stock, go to TipRanks’ Stock Analysis page.